Themis Medicare Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
287.60 +1.20 (0.42%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
284.25
Today’s High
294.35
52 Week Low
152.65
52 Week High
313.65
287.70 +1.50 (0.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
284
Today’s High
294.3
52 Week Low
152.8
52 Week High
317
Key Metrics
- Market Cap (In Cr) 2634.19
- Beta 1.2
- Div. Yield (%) 0.17
- P/B 6.97
- TTM P/E 47.5
- Peg Ratio 7.41
- Sector P/E 31.15
- D/E 0.2
- Open Price 294.35
- Prev Close 286.4
Themis Medicare Analysis
Price Analysis
-
1 Week3.68%
-
3 Months8.68%
-
6 Month38.5%
-
YTD33.93%
-
1 Year84.23%
Risk Meter
- 48% Low risk
- 48% Moderate risk
- 48% Balanced Risk
- 48% High risk
- 48% Extreme risk
Themis Medicare News
Stocks to Watch: Zee, Waaree Energies, Bharti Airtel, NTPC, GVK Power and more
1 min read . 19 Nov 2024Themis Medicare Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 381.76
- Selling/ General/ Admin Expenses Total
- 82.41
- Depreciation/ Amortization
- 12.25
- Other Operating Expenses Total
- 111.13
- Total Operating Expense
- 342.5
- Operating Income
- 39.26
- Net Income Before Taxes
- 53.44
- Net Income
- 43.52
- Diluted Normalized EPS
- 4.72
- Period
- 2024
- Total Assets
- 566.42
- Total Liabilities
- 188.75
- Total Equity
- 377.67
- Tangible Book Valueper Share Common Eq
- 40.97
- Period
- 2024
- Cashfrom Operating Activities
- 22.09
- Cashfrom Investing Activities
- -15.95
- Cashfrom Financing Activities
- -8.77
- Net Changein Cash
- -2.62
- Period
- 2023
- Total Revenue
- 354.32
- Selling/ General/ Admin Expenses Total
- 131.54
- Depreciation/ Amortization
- 10.49
- Other Operating Expenses Total
- 20.4
- Total Operating Expense
- 297.37
- Operating Income
- 56.96
- Net Income Before Taxes
- 72.51
- Net Income
- 56.9
- Diluted Normalized EPS
- 6.17
- Period
- 2023
- Total Assets
- 513.96
- Total Liabilities
- 174.51
- Total Equity
- 339.44
- Tangible Book Valueper Share Common Eq
- 36.8
- Period
- 2023
- Cashfrom Operating Activities
- 16.09
- Cashfrom Investing Activities
- -23.96
- Cashfrom Financing Activities
- 0.14
- Net Changein Cash
- -7.73
- Period
- 2022
- Total Revenue
- 394.61
- Selling/ General/ Admin Expenses Total
- 111.63
- Depreciation/ Amortization
- 9.48
- Other Operating Expenses Total
- 18.86
- Total Operating Expense
- 308.46
- Operating Income
- 86.16
- Net Income Before Taxes
- 95.26
- Net Income
- 72.88
- Diluted Normalized EPS
- 7.91
- Period
- 2022
- Total Assets
- 427.78
- Total Liabilities
- 140.29
- Total Equity
- 287.49
- Tangible Book Valueper Share Common Eq
- 31.14
- Period
- 2022
- Cashfrom Operating Activities
- 34.39
- Cashfrom Investing Activities
- -15.59
- Cashfrom Financing Activities
- -17.55
- Net Changein Cash
- 1.26
- Period
- 2021
- Total Revenue
- 230.67
- Selling/ General/ Admin Expenses Total
- 79.82
- Depreciation/ Amortization
- 8.55
- Other Operating Expenses Total
- 14.16
- Total Operating Expense
- 189.72
- Operating Income
- 40.95
- Net Income Before Taxes
- 41.33
- Net Income
- 35.7
- Diluted Normalized EPS
- 3.88
- Period
- 2021
- Total Assets
- 371.14
- Total Liabilities
- 152.63
- Total Equity
- 218.51
- Tangible Book Valueper Share Common Eq
- 23.65
- Period
- 2021
- Cashfrom Operating Activities
- 56.98
- Cashfrom Investing Activities
- -15.65
- Cashfrom Financing Activities
- -25.65
- Net Changein Cash
- 15.68
- Period
- 2020
- Total Revenue
- 201.59
- Selling/ General/ Admin Expenses Total
- 83.46
- Depreciation/ Amortization
- 8.27
- Other Operating Expenses Total
- 7.79
- Total Operating Expense
- 174.13
- Operating Income
- 27.46
- Net Income Before Taxes
- 26.87
- Net Income
- 24.78
- Diluted Normalized EPS
- 2.7
- Period
- 2020
- Total Assets
- 349.91
- Total Liabilities
- 166.89
- Total Equity
- 183.02
- Tangible Book Valueper Share Common Eq
- 19.76
- Period
- 2020
- Cashfrom Operating Activities
- 0.33
- Cashfrom Investing Activities
- -5.47
- Cashfrom Financing Activities
- 6.72
- Net Changein Cash
- 1.59
- Period
- 2019
- Total Revenue
- 183.75
- Selling/ General/ Admin Expenses Total
- 89.4
- Depreciation/ Amortization
- 7.99
- Other Operating Expenses Total
- 8.64
- Total Operating Expense
- 184.96
- Operating Income
- -1.2
- Net Income Before Taxes
- -12.6
- Net Income
- -10.74
- Diluted Normalized EPS
- -1.17
- Period
- 2019
- Total Assets
- 314.11
- Total Liabilities
- 156.02
- Total Equity
- 158.09
- Tangible Book Valueper Share Common Eq
- 17.04
- Period
- 2019
- Cashfrom Operating Activities
- 10.92
- Cashfrom Investing Activities
- -3.72
- Cashfrom Financing Activities
- -9.94
- Net Changein Cash
- -2.74
- Period
- 2018
- Total Revenue
- 211.71
- Selling/ General/ Admin Expenses Total
- 90.88
- Depreciation/ Amortization
- 7.42
- Other Operating Expenses Total
- 9.35
- Total Operating Expense
- 193.94
- Operating Income
- 17.77
- Net Income Before Taxes
- 11.34
- Net Income
- 11.3
- Diluted Normalized EPS
- 1.23
- Period
- 2018
- Total Assets
- 305.28
- Total Liabilities
- 136.38
- Total Equity
- 168.91
- Tangible Book Valueper Share Common Eq
- 18.19
- Period
- 2018
- Cashfrom Operating Activities
- 7.85
- Cashfrom Investing Activities
- -0.04
- Cashfrom Financing Activities
- -9.11
- Net Changein Cash
- -1.3
- Period
- 2024-09-30
- Total Revenue
- 117.01
- Selling/ General/ Admin Expenses Total
- 24.38
- Depreciation/ Amortization
- 2.45
- Other Operating Expenses Total
- 33.87
- Total Operating Expense
- 102.33
- Operating Income
- 14.68
- Net Income Before Taxes
- 17.8
- Net Income
- 14.29
- Diluted Normalized EPS
- 1.55
- Period
- 2024-09-30
- Total Assets
- 602.21
- Total Liabilities
- 190.2
- Total Equity
- 412.02
- Tangible Book Valueper Share Common Eq
- 44.72
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 32.97
- Cashfrom Investing Activities
- -9.98
- Cashfrom Financing Activities
- -23.21
- Net Changein Cash
- -0.22
- Period
- 2024-06-30
- Total Revenue
- 122.99
- Selling/ General/ Admin Expenses Total
- 21.6
- Depreciation/ Amortization
- 2.41
- Other Operating Expenses Total
- 30.95
- Total Operating Expense
- 96.22
- Operating Income
- 26.77
- Net Income Before Taxes
- 31.35
- Net Income
- 24.68
- Diluted Normalized EPS
- 2.68
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 97.82
- Selling/ General/ Admin Expenses Total
- 22.46
- Depreciation/ Amortization
- 3.06
- Other Operating Expenses Total
- 26.83
- Total Operating Expense
- 91.58
- Operating Income
- 6.24
- Net Income Before Taxes
- 8.75
- Net Income
- 6.64
- Diluted Normalized EPS
- 0.72
- Period
- 2024-03-31
- Total Assets
- 566.42
- Total Liabilities
- 188.75
- Total Equity
- 377.67
- Tangible Book Valueper Share Common Eq
- 40.97
- Period
- 2024-03-31
- Period
- 2023-12-31
- Total Revenue
- 82.51
- Selling/ General/ Admin Expenses Total
- 19.92
- Depreciation/ Amortization
- 3.1
- Other Operating Expenses Total
- 28.05
- Total Operating Expense
- 77.55
- Operating Income
- 4.97
- Net Income Before Taxes
- 8.22
- Net Income
- 7.37
- Diluted Normalized EPS
- 0.8
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 104.78
- Selling/ General/ Admin Expenses Total
- 19.86
- Depreciation/ Amortization
- 3.07
- Other Operating Expenses Total
- 30.58
- Total Operating Expense
- 95.45
- Operating Income
- 9.34
- Net Income Before Taxes
- 13.96
- Net Income
- 11.32
- Diluted Normalized EPS
- 1.23
- Period
- 2023-09-30
- Total Assets
- 548.47
- Total Liabilities
- 184.33
- Total Equity
- 364.14
- Tangible Book Valueper Share Common Eq
- 39.5
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 16.7
- Cashfrom Investing Activities
- -9.84
- Cashfrom Financing Activities
- -5.93
- Net Changein Cash
- 0.93
- Period
- 2023-06-30
- Total Revenue
- 96.65
- Selling/ General/ Admin Expenses Total
- 20.17
- Depreciation/ Amortization
- 3.02
- Other Operating Expenses Total
- 25.67
- Total Operating Expense
- 77.93
- Operating Income
- 18.72
- Net Income Before Taxes
- 22.52
- Net Income
- 18.19
- Diluted Normalized EPS
- 1.97
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 80.1
- Selling/ General/ Admin Expenses Total
- 17.72
- Depreciation/ Amortization
- 2.8
- Other Operating Expenses Total
- 24.1
- Total Operating Expense
- 72.42
- Operating Income
- 7.68
- Net Income Before Taxes
- 10.29
- Net Income
- 8.41
- Diluted Normalized EPS
- 0.91
- Period
- 2023-03-31
- Total Assets
- 513.96
- Total Liabilities
- 174.51
- Total Equity
- 339.44
- Tangible Book Valueper Share Common Eq
- 36.8
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 16.09
- Cashfrom Investing Activities
- -23.96
- Cashfrom Financing Activities
- 0.14
- Net Changein Cash
- -7.73
- Period
- 2022-12-31
- Total Revenue
- 88.78
- Selling/ General/ Admin Expenses Total
- 16.62
- Depreciation/ Amortization
- 2.67
- Other Operating Expenses Total
- 23.46
- Total Operating Expense
- 76.19
- Operating Income
- 12.59
- Net Income Before Taxes
- 17.5
- Net Income
- 13.31
- Diluted Normalized EPS
- 1.44
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Themis Medicare Technical
Moving Average
SMA
- 5 Day276.75
- 10 Day276.04
- 20 Day269.7
- 50 Day270.19
- 100 Day254.33
- 300 Day238.41
Themis Medicare Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Astrazeneca Pharma India
- 6304.95
- -192.55
- -2.96
- 8139.85
- 4050.15
- 15762.38
- Unichem Laboratories
- 860.7
- -20.9
- -2.37
- 949.85
- 401.1
- 6059.82
- Themis Medicare
- 287.6
- 1.2
- 0.42
- 313.65
- 152.65
- 2647.07
- Jagsonpal Pharmaceuticals
- 591.65
- 13.55
- 2.34
- 634.95
- 270.05
- 1564.19
- Ind-Swift Laboratories
- 106
- 1.95
- 1.87
- 186
- 89.5
- 626.32
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Astrazeneca Pharma India
- 108.05
- 22.81
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.63
- -2.1
- -3.99
- Themis Medicare
- 60.63
- 6.97
- 18.03
- 14.96
- Jagsonpal Pharmaceuticals
- 66.37
- 8.13
- 13.79
- 9.21
- Ind-Swift Laboratories
- 4.41
- 0.66
- 13.45
- 8.52
Themis Medicare Shareholding
Shareholding Pattern
*Promoter pledging: 1.63%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 14-May-24
- Audited Results & Final Dividend
- 10-Feb-24
- Quarterly Results
- 04-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 10-Aug-23
- Quarterly Results
- 13-May-23
- Audited Results, Dividend & Stock Split
- 03-Feb-23
- Quarterly Results
- 07-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 22-Jul-24
- 15-May-24
- AGM
- 09-Apr-24
- 11-Mar-24
- POM
- 17-Nov-23
- 16-Oct-23
- POM
- 09-Sept-23
- 22-Jul-23
- AGM
- 19-Sept-22
- 23-May-22
- AGM
- 20-Jun-22
- 17-May-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 14-May-24
- -
- 12-Jul-24
- 0.5
- 15-May-23
- -
- 01-Sept-23
- 5
- 23-May-22
- -
- 08-Sept-22
- 5
- 27-May-21
- -
- 08-Sept-21
- 4.3
- Ex-Splits
- Old FV
- New FV
- Description
- 10-Oct-23
- 10
- 1
- Stock split from Rs. 10/- to Re. 1/-.